News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
US High Court Rejects Wyeth Appeal In Hormone-Therapy Case
June 22, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
The U.S. Supreme Court on Monday rejected an appeal by Pfizer Inc.'s (PFE) Wyeth unit of a $58 million Nevada judgment in favor of three women who claimed they developed breast cancer due to their use of the company's hormone-therapy.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Policy
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
October 23, 2026
·
2 min read
·
Nick Paul Taylor
Job Trends
As H-1B visa changes keep coming, biopharmas adjust hiring approach
October 22, 2026
·
5 min read
·
Angela Gabriel
Legal
‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban
October 14, 2026
·
4 min read
·
Annalee Armstrong
Manufacturing
Merck barred from making subcutaneous Keytruda in 8 European countries
October 8, 2026
·
2 min read
·
Nick Paul Taylor